Abstract
Recent phase I and phase II trials using recombinant human interleukin-12 (rhIL-12) for cutaneous T cell lymphoma (CTCL) have been completed. Observations on 32 evaluable patients revealed an overall response rate approaching 50 percent. Biopsy of regressing lesions revealed an increase in numbers of CD8+ and/or TIA-1+ T cells. These results suggest that rhIL-12 may induce lesion regression by augmenting antitumor cytotoxic T cell responses. Future trials will be focused on strategies for further immune enhancement by the concomitant use of additional immune augmenting cytokines with rhIL-12.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase I
-
Clinical Trial, Phase II
-
Controlled Clinical Trial
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Antigens, Differentiation, T-Lymphocyte / analysis
-
Antigens, Differentiation, T-Lymphocyte / immunology
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Humans
-
Immunohistochemistry
-
Interleukin-12 / adverse effects
-
Interleukin-12 / therapeutic use*
-
Lymphocytes, Tumor-Infiltrating / immunology
-
Lymphoma, T-Cell, Cutaneous / drug therapy*
-
Lymphoma, T-Cell, Cutaneous / immunology
-
Recombinant Proteins / therapeutic use
-
Skin Neoplasms / drug therapy*
-
Skin Neoplasms / immunology
-
T-Lymphocyte Subsets / classification
-
T-Lymphocytes, Cytotoxic / immunology
-
Treatment Outcome
Substances
-
Antigens, Differentiation, T-Lymphocyte
-
Antineoplastic Agents
-
Recombinant Proteins
-
Interleukin-12